Roche Reports P-III Study (ALINA) Results of Alecensa (alectinib) for ALK-Positive Early-Stage Lung Cancer
Shots:
- The P-III study evaluating adjuvant Alecensa (ALK inhibitor) vs Pt-based CT in 257 patients with completely resected stage IB (tumor≥4cm) to IIIA anaplastic lymphoma kinase (ALK)-positive NSCLC
- The trial met its 1EPs of DFS at a prespecified interim analysis & showed a significant and clinical improvement in DFS while the OS were immature at the time of this analysis & no unexpected safety findings were reported
- The results will be submitted to health authorities globally incl. the US FDA and EMA and presented at an upcoming medical meeting. Alecensa was approved in ~100 countries as a 1L treatment for ALK+, metastatic NSCLC, incl. in the US, EU, Japan, and China
Ref: Globenewswire | Image: Roche
Related News:- Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
